Compare ARK Genomic Revolution ETF (ARKG) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs VF Corp — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while VF Corp trades at $16.74 (market cap $6.58B). The key difference: VF Corp pays a 2.15% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, VF Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | VFC | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $21.55 |
52-Week Low | $23.09 | $11.66 |
Market Cap | — | $6.58B |
Enterprise Value | — | $10.73B |
Dividend Yield | — | 2.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VFC trades at $16.77, up 1.45% on the day, amid a mixed technical and fundamental backdrop. The stock is bearish on moving averages but shows neutral oscillators, with key support at $16. Recent earnings have been volatile, with a Q1 2026 miss after previous beats, while revenue has declined from $11.8B in 2022 to $9.5B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M for 2025. Analyst sentiment is mixed with a consensus price target of $20.00.
The outlook for VFC hinges on a successful turnaround, with projected net income turning positive in 2026. Near-term risks include weak consumer confidence and brand-specific challenges at Vans. The current valuation, with a P/S of 0.69, may appeal to value investors if operational improvements continue, but execution risks and high debt levels warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
